Press release
GM2 Gangliosidosis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), Analyzes DelveInsight | Azafaros A.G., IntraBio, Children's National Research Institute, Sanofi
To Know in detail about the GM2 Gangliosidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GM2 Gangliosidosis Market Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the GM2 Gangliosidosis Market Report:
• The GM2 Gangliosidosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• According to the analysis, approximately seventy cases of GM2 gangliosidosis were documented in the United Kingdom, with around forty individuals diagnosed with Tay-Sachs disease, thirty with Sandhoff disease, and two with GM2 activator protein deficiency.
• According to DelveInsight's analysis, in the United States, the incidence of TSD is approximately 1 in every 320,000 live births, while the carrier frequency is around 1 in 250 individuals.
• Approximately 30 patients were identified with mutations in the HEXA gene, while around fifteen patients exhibited defects in the HEXB gene. Among Tay-Sachs patients, about twenty individuals manifested the infantile form of the disease, with the age of diagnosis spanning from 7 months to 3 years.
• Key GM2 Gangliosidosis Companies: Azafaros A.G., IntraBio, Children's National Research Institute, Sanofi, and others
• Key GM2 Gangliosidosis Therapies: AZ-3102 (nizubaglustat), IB1001, Zavesca (Miglustat), venglustat GZ402671, and others
• The GM2 Gangliosidosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage GM2 Gangliosidosis pipeline products will significantly revolutionize the GM2 Gangliosidosis market dynamics.
GM2 Gangliosidosis Overview
GM2 gangliosidosis is a group of rare, inherited neurodegenerative disorders caused by the accumulation of GM2 ganglioside, a type of fatty substance, in the nerve cells of the brain and spinal cord. This accumulation results from a deficiency in specific enzymes needed to break down GM2 ganglioside. GM2 gangliosidosis is divided into two main types: Tay-Sachs disease and Sandhoff disease.
Get a Free sample for the GM2 Gangliosidosis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
GM2 Gangliosidosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
GM2 Gangliosidosis Epidemiology Segmentation:
The GM2 Gangliosidosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of GM2 Gangliosidosis
• Prevalent Cases of GM2 Gangliosidosis by severity
• Gender-specific Prevalence of GM2 Gangliosidosis
• Diagnosed Cases of Episodic and Chronic GM2 Gangliosidosis
Download the report to understand which factors are driving GM2 Gangliosidosis epidemiology trends @ GM2 Gangliosidosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
GM2 Gangliosidosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the GM2 Gangliosidosis market or expected to get launched during the study period. The analysis covers GM2 Gangliosidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the GM2 Gangliosidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
GM2 Gangliosidosis Therapies and Key Companies
• AZ-3102 (nizubaglustat): Azafaros A.G.
• IB1001: IntraBio
• Zavesca (Miglustat): Children's National Research Institute
• venglustat GZ402671: Sanofi
Discover more about therapies set to grab major GM2 Gangliosidosis market share @ GM2 Gangliosidosis Treatment Landscape
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of the GM2 Gangliosidosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key GM2 Gangliosidosis Companies: Azafaros A.G., IntraBio, Children's National Research Institute, Sanofi, and others
• Key GM2 Gangliosidosis Therapies: AZ-3102 (nizubaglustat), IB1001, Zavesca (Miglustat), venglustat GZ402671, and others
• GM2 Gangliosidosis Therapeutic Assessment: GM2 Gangliosidosis current marketed and GM2 Gangliosidosis emerging therapies
• GM2 Gangliosidosis Market Dynamics: GM2 Gangliosidosis market drivers and GM2 Gangliosidosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• GM2 Gangliosidosis Unmet Needs, KOL's views, Analyst's views, GM2 Gangliosidosis Market Access and Reimbursement
To know more about GM2 Gangliosidosis companies working in the treatment market, visit @ GM2 Gangliosidosis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. GM2 Gangliosidosis Market Report Introduction
2. Executive Summary for GM2 Gangliosidosis
3. SWOT analysis of GM2 Gangliosidosis
4. GM2 Gangliosidosis Patient Share (%) Overview at a Glance
5. GM2 Gangliosidosis Market Overview at a Glance
6. GM2 Gangliosidosis Disease Background and Overview
7. GM2 Gangliosidosis Epidemiology and Patient Population
8. Country-Specific Patient Population of GM2 Gangliosidosis
9. GM2 Gangliosidosis Current Treatment and Medical Practices
10. GM2 Gangliosidosis Unmet Needs
11. GM2 Gangliosidosis Emerging Therapies
12. GM2 Gangliosidosis Market Outlook
13. Country-Wise GM2 Gangliosidosis Market Analysis (2020-2034)
14. GM2 Gangliosidosis Market Access and Reimbursement of Therapies
15. GM2 Gangliosidosis Market Drivers
16. GM2 Gangliosidosis Market Barriers
17. GM2 Gangliosidosis Appendix
18. GM2 Gangliosidosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
GM2 Gangliosidosis Pipeline https://www.delveinsight.com/report-store/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"GM2 Gangliosidosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the GM2 Gangliosidosis market. A detailed picture of the GM2 Gangliosidosis pipeline landscape is provided, which includes the disease overview and GM2 Gangliosidosis treatment guidelines.
Latest Reports by DelveInsight
Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Dermatitis Seborrheic Market https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
DelveInsight's "Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Gastro Intestinal Bleeding Market https://www.delveinsight.com/report-store/gastro-intestinal-bleeding-market
DelveInsight's "Gastro Intestinal Bleeding Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastro Intestinal Bleeding, historical and forecasted epidemiology as well as the Gastro Intestinal Bleeding market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
DelveInsight's comprehensive report titled "Listeriosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Listeriosis. The report presents historical and projected epidemiological data covering incident cases of listeriosis, age-specific cases of listeriosis, gender-specific cases of listeriosis, risk-associated cases of listeriosis, and treated cases of listeriosis.
Point Of Care Glucose Testing Market https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Substance Drug Abuse Market https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GM2 Gangliosidosis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), Analyzes DelveInsight | Azafaros A.G., IntraBio, Children's National Research Institute, Sanofi here
News-ID: 3516484 • Views: …
More Releases from DelveInsight Business Research
Bardet-Biedl Syndrome Market Outlook 2034 - Clinical Trials, Market Size, Medica …
DelveInsight's recent publication, "Bardet-Biedl Syndrome Market Insight, Epidemiology, and Market Forecast - 2034," delivers an exhaustive examination of the evolving therapeutic and diagnostic landscape of this rare condition.
The report encompasses major markets, including the United States, the EU4 nations (Germany, France, Italy, Spain), the United Kingdom, and Japan. It highlights existing shortcomings in diagnostic capabilities and therapeutic options while providing insights into emerging strategies designed to improve management of Bardet-Biedl…
Global GM2 Gangliosidosis Clinical Trials 2025: Drug Pipeline, Regulatory Approv …
DelveInsight's "GM2 Gangliosidosis - Pipeline Insight, 2025" delivers an in-depth evaluation of the global research and development landscape, profiling both clinical and preclinical drug candidates with varied mechanisms of action. The report explores key advancements including AAV-based gene therapies focused on the central nervous system, innovations in delivery technologies, and novel approaches aimed at improving long-term safety and efficacy. It also examines shifting regulatory frameworks, biomarker-guided clinical trial designs, and…
Global Basal Cell Nevus Syndrome Clinical Trials 2025: Drug Pipeline, Regulatory …
DelveInsight's "Basal Cell Nevus Syndrome (BCNS) - Pipeline Insight, 2025" provides an in-depth analysis of both current and forthcoming treatment options. The report covers therapies in clinical and preclinical stages, highlights innovative drug delivery technologies, and examines efforts to tailor treatments through genetic profiling. It also reviews regulatory advancements, rare disease designations, and key collaborations driving progress in this specialized yet critical area.
As the pipeline advances, a shift from managing…
Global Cerebral Amyloid Angiopathy Clinical Trials 2025: Drug Pipeline, Regulato …
DelveInsight's "Cerebral Amyloid Angiopathy Pipeline Insight, 2025" provides an in-depth analysis of the current and emerging therapeutic landscape for Cerebral Amyloid Angiopathy (CAA). The report comprehensively profiles ongoing clinical and preclinical development programs targeting disease modification, evaluates investigational imaging biomarkers to enhance early and accurate diagnosis, and examines regulatory frameworks alongside translational research initiatives that are accelerating drug development in this historically under-recognized cerebrovascular disorder.
With increasing awareness of Cerebral Amyloid…
More Releases for GM2
GM2 Gangliosidosis Market Set to Advance Through 2034, Fueled by Gene Therapy In …
GM2 Gangliosidosis refers to a group of rare, inherited lysosomal storage disorders-including Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency-caused by mutations that impair the breakdown of GM2 gangliosides in nerve cells. These disorders are characterized by progressive neurodegeneration, muscle weakness, motor impairment, seizures, and early mortality, especially in infantile-onset forms. The most common types, Tay-Sachs and Sandhoff disease, result from mutations in the HEXA and HEXB genes, respectively.
DelveInsight's report,…
GM2 Gangliosidosis Pipeline Overview: 8+ Innovative Therapies Driving Hope in Ra …
The therapeutic landscape for GM2 gangliosidosis-an ultra-rare, inherited lysosomal storage disorder encompassing Tay-Sachs and Sandhoff diseases-is witnessing growing innovation, with the pipeline evolving toward more disease-modifying and potentially curative therapies. GM2 gangliosidosis is caused by mutations affecting β-hexosaminidase A and/or B enzymes, resulting in the toxic accumulation of GM2 gangliosides in neurons, which leads to progressive neurodegeneration. Despite the severity of this disease, current management remains largely supportive, highlighting an…
Tay-Sachs Disease Pipeline 2025: Groundbreaking Clinical Advancements by 4+ Glob …
With Tay-Sachs Disease reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Tay-Sachs Disease pipeline comprises 4+ pharmaceutical and biotech companies actively developing 5+ therapeutic candidates targeting Tay-Sachs Disease. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to…
GM2 Gangliosidosis Pipeline Assessment 2024 | Clinical Trials, Therapies, Latest …
(Albany, USA) "GM2 Gangliosidosis Pipeline Insight, 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the GM2 Gangliosidosis Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products…
GM2 Gangliosidosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging T …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 8+ pipeline drugs in the GM2 Gangliosidosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"GM2 Gangliosidosis Pipeline Insight, 2023" report…
GM2 Gangliosidosis Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging …
GM2 Gangliosidosis pipeline constitutes 8+ key companies continuously working towards developing 8+ GM2 Gangliosidosis treatment therapies, analyzes DelveInsight
GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay-Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic…
